BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Press Releases

  bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

  January 8, 2026

   · 

  5 min read
• Press Releases

  Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma

  January 8, 2026

   · 

  3 min read
• Press Releases

  NeuraLight Reaches Key Milestone with Completion of International Multicenter Parkinson’s Clinical Trial

  January 8, 2026

   · 

  4 min read
• Press Releases

  FDA and EMA Grant Orphan Drug Designation for Curadel’s CPI-008, a Targeted Zwitterionic Imaging Drug for Pancreatic Cancer

  January 8, 2026

   · 

  2 min read
• Press Releases

  Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

  January 8, 2026

   · 

  10 min read
• Press Releases

  Soley Therapeutics Announces $200 Million Series C Financing to Propel Lead Oncology Programs into the Clinic and Scale Its Cell Stress Sensing Platform

  January 8, 2026

   · 

  2 min read
• Press Releases

  Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

  January 8, 2026

   · 

  5 min read
• Press Releases

  Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease

  January 8, 2026

   · 

  3 min read
• Press Releases

  Corsera Health Announces $80 Million Series A Financing and Reaches Key Clinical Milestone

  January 8, 2026

   · 

  5 min read
• Press Releases

  Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate

  January 8, 2026

   · 

  3 min read